| Date:_2022-3-28  |
|--|
| Your Name:_Yongfei He  |
| Manuscript Title:_Effects of 2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione on autophagy and the PI3K/AKT/mTOR |
| signaling pathway in human cholangiocarcinoma QBC939 cells   |
| Manuscript number (if known):  |
|  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None   |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | None   |   |
| 3 | Royalties or licenses   | None   |   |
| 4 | Consulting fees   | None   |   |

| 5   | Payment or honoraria for lectures, presentations,                     | None |  |  |  |
|-----|---|------|--|--|--|
|     |   |      |  |  |  |
|     | speakers bureaus,   |      |  |  |  |
|     | manuscript writing or   |      |  |  |  |
|     | educational events  |      |  |  |  |
| 6   | Payment for expert testimony  | None |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| 7   | Support for attending   | None |  |  |  |
|     | meetings and/or travel  |      |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| 8   | Patents planned, issued or  | None |  |  |  |
|     | pending   |      |  |  |  |
|     |   |      |  |  |  |
| 9   | Participation on a Data   | None |  |  |  |
|     | Safety Monitoring Board or<br>Advisory Board                          |      |  |  |  |
|     |   |      |  |  |  |
| 10  | Leadership or fiduciary role  | None |  |  |  |
|     | in other board, society,  |      |  |  |  |
|     | committee or advocacy   |      |  |  |  |
|     | group, paid or unpaid   |      |  |  |  |
| 11  | Stock or stock options  | None |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| 12  | Receipt of equipment,<br>materials, drugs, medical                    | None |  |  |  |
|     |   |      |  |  |  |
|     | writing, gifts or other services                                      |      |  |  |  |
| 13  | Other financial or non-   | None |  |  |  |
| 13  | financial interests   | None |  |  |  |
|     | illialiciai illielesis  |      |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| PΙΔ | Please summarize the above conflict of interest in the following box: |      |  |  |  |
|     |   |      |  |  |  |
|     | The author has no conflicts of interest to declare.                   |      |  |  |  |

| Date:_2022-3-28  |    |
|--|----|
| Your Name:_Yanghong Li   |    |
| Manuscript Title:_Effects of 2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione on autophagy and the PI3K/AKT/mT | OR |
| signaling pathway in human cholangiocarcinoma QBC939 cells   |    |
| Manuscript number (if known):  |    |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | None   |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | None   |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | None   |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | None   |   |
|   |                               |  |   |

| 5   | Payment or honoraria for lectures, presentations,                     | None |  |  |  |
|-----|---|------|--|--|--|
|     |   |      |  |  |  |
|     | speakers bureaus,   |      |  |  |  |
|     | manuscript writing or   |      |  |  |  |
|     | educational events  |      |  |  |  |
| 6   | Payment for expert testimony  | None |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| 7   | Support for attending   | None |  |  |  |
|     | meetings and/or travel  |      |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| 8   | Patents planned, issued or  | None |  |  |  |
|     | pending   |      |  |  |  |
|     |   |      |  |  |  |
| 9   | Participation on a Data   | None |  |  |  |
|     | Safety Monitoring Board or<br>Advisory Board                          |      |  |  |  |
|     |   |      |  |  |  |
| 10  | Leadership or fiduciary role  | None |  |  |  |
|     | in other board, society,  |      |  |  |  |
|     | committee or advocacy   |      |  |  |  |
|     | group, paid or unpaid   |      |  |  |  |
| 11  | Stock or stock options  | None |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| 12  | Receipt of equipment,<br>materials, drugs, medical                    | None |  |  |  |
|     |   |      |  |  |  |
|     | writing, gifts or other services                                      |      |  |  |  |
| 13  | Other financial or non-   | None |  |  |  |
| 13  | financial interests   | None |  |  |  |
|     | illialiciai illielesis  |      |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| PΙΔ | Please summarize the above conflict of interest in the following box: |      |  |  |  |
|     |   |      |  |  |  |
|     | The author has no conflicts of interest to declare.                   |      |  |  |  |

| Date:_2022-3-28  |    |
|--|----|
| Your Name:_Tianyi Liang  |    |
| Manuscript Title:_Effects of 2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione on autophagy and the PI3K/AKT/mT | OR |
| signaling pathway in human cholangiocarcinoma QBC939 cells   |    |
| Manuscript number (if known):  |    |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | None   |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | None   |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | None   |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | None   |   |
|   |                               |  |   |

| 5   | Payment or honoraria for lectures, presentations,                     | None |  |  |  |
|-----|---|------|--|--|--|
|     |   |      |  |  |  |
|     | speakers bureaus,   |      |  |  |  |
|     | manuscript writing or   |      |  |  |  |
|     | educational events  |      |  |  |  |
| 6   | Payment for expert testimony  | None |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| 7   | Support for attending   | None |  |  |  |
|     | meetings and/or travel  |      |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| 8   | Patents planned, issued or  | None |  |  |  |
|     | pending   |      |  |  |  |
|     |   |      |  |  |  |
| 9   | Participation on a Data   | None |  |  |  |
|     | Safety Monitoring Board or<br>Advisory Board                          |      |  |  |  |
|     |   |      |  |  |  |
| 10  | Leadership or fiduciary role  | None |  |  |  |
|     | in other board, society,  |      |  |  |  |
|     | committee or advocacy   |      |  |  |  |
|     | group, paid or unpaid   |      |  |  |  |
| 11  | Stock or stock options  | None |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| 12  | Receipt of equipment,<br>materials, drugs, medical                    | None |  |  |  |
|     |   |      |  |  |  |
|     | writing, gifts or other services                                      |      |  |  |  |
| 13  | Other financial or non-   | None |  |  |  |
| 13  | financial interests   | None |  |  |  |
|     | illialiciai illielesis  |      |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| PΙΔ | Please summarize the above conflict of interest in the following box: |      |  |  |  |
|     |   |      |  |  |  |
|     | The author has no conflicts of interest to declare.                   |      |  |  |  |

| Date:_2022-3-28  |     |
|--|-----|
| Your Name:Shutian Mo   |     |
| Manuscript Title:_Effects of 2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione on autophagy and the PI3K/AKT/mT | ΓOR |
| signaling pathway in human cholangiocarcinoma QBC939 cells   |     |
| Manuscript number (if known):  |     |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
|   | All  | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, | None   |   |
|   | provision of study materials,                          |  |   |
|   | medical writing, article                               |  |   |
|   | processing charges, etc.)                              |  |   |
|   | No time limit for this item.                           |  |   |
|   |  |  |   |
|   |  |  |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from                               | None   |   |
|   | any entity (if not indicated                           |  |   |
|   | in item #1 above).                                     |  |   |
| 3 | Royalties or licenses                                  | None   |   |
|   |  |  |   |
|   |  |  |   |
| 4 | Consulting fees  | None   |   |
|   |  |  |   |

| 5   | Payment or honoraria for lectures, presentations,                     | None |  |  |  |
|-----|---|------|--|--|--|
|     |   |      |  |  |  |
|     | speakers bureaus,   |      |  |  |  |
|     | manuscript writing or   |      |  |  |  |
|     | educational events  |      |  |  |  |
| 6   | Payment for expert testimony  | None |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| 7   | Support for attending   | None |  |  |  |
|     | meetings and/or travel  |      |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| 8   | Patents planned, issued or  | None |  |  |  |
|     | pending   |      |  |  |  |
|     |   |      |  |  |  |
| 9   | Participation on a Data   | None |  |  |  |
|     | Safety Monitoring Board or<br>Advisory Board                          |      |  |  |  |
|     |   |      |  |  |  |
| 10  | Leadership or fiduciary role  | None |  |  |  |
|     | in other board, society,  |      |  |  |  |
|     | committee or advocacy   |      |  |  |  |
|     | group, paid or unpaid   |      |  |  |  |
| 11  | Stock or stock options  | None |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| 12  | Receipt of equipment,<br>materials, drugs, medical                    | None |  |  |  |
|     |   |      |  |  |  |
|     | writing, gifts or other services                                      |      |  |  |  |
| 13  | Other financial or non-   | None |  |  |  |
| 13  | financial interests   | None |  |  |  |
|     | illialiciai illielesis  |      |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| PΙΔ | Please summarize the above conflict of interest in the following box: |      |  |  |  |
|     |   |      |  |  |  |
|     | The author has no conflicts of interest to declare.                   |      |  |  |  |

| Date:_2022-3-28   |     |
|---|-----|
| Your Name:Yuan Liao   |     |
| Manuscript Title:_Effects of 2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione on autophagy and the PI3K/AKT/m | TOR |
| signaling pathway in human cholangiocarcinoma QBC939 cells  |     |
| Manuscript number (if known):   |     |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None   |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | None   |   |
| 3 | Royalties or licenses   | None   |   |
| 4 | Consulting fees   | None   |   |

| 5   | Payment or honoraria for  | None |  |  |  |
|-----|---|------|--|--|--|
|     | lectures, presentations,  |      |  |  |  |
|     | speakers bureaus,   |      |  |  |  |
|     | manuscript writing or   |      |  |  |  |
|     | educational events  |      |  |  |  |
| 6   | Payment for expert testimony  | None |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| 7   | Support for attending   | None |  |  |  |
|     | meetings and/or travel  |      |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| 8   | Patents planned, issued or  | None |  |  |  |
|     | pending   |      |  |  |  |
|     |   |      |  |  |  |
| 9   | Participation on a Data   | None |  |  |  |
|     | Safety Monitoring Board or  |      |  |  |  |
|     | Advisory Board  |      |  |  |  |
| 10  | Leadership or fiduciary role  | None |  |  |  |
|     | in other board, society,  |      |  |  |  |
|     | committee or advocacy   |      |  |  |  |
|     | group, paid or unpaid   |      |  |  |  |
| 11  | Stock or stock options  | None |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| 12  | Receipt of equipment,<br>materials, drugs, medical                    | None |  |  |  |
|     |   |      |  |  |  |
|     | writing, gifts or other   |      |  |  |  |
| 13  | services  Other financial or non-                                     | None |  |  |  |
| 13  | financial interests   | None |  |  |  |
|     | illialiciai illielesis  |      |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| PΙΔ | Please summarize the above conflict of interest in the following box: |      |  |  |  |
|     |   |      |  |  |  |
|     | The author has no conflicts of interest to declare.                   |      |  |  |  |

| Date:_2022-3-28   |    |
|---|----|
| Your Name:_Zijun Chen   |    |
| Manuscript Title:_Effects of 2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione on autophagy and the PI3K/AKT/mT0 | OR |
| signaling pathway in human cholangiocarcinoma QBC939 cells  |    |
| Manuscript number (if known):   |    |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | None   |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | None   |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | None   |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | None   |   |
|   |                               |  |   |

| 5   | Payment or honoraria for  | None |  |  |  |
|-----|---|------|--|--|--|
|     | lectures, presentations,  |      |  |  |  |
|     | speakers bureaus,   |      |  |  |  |
|     | manuscript writing or   |      |  |  |  |
|     | educational events  |      |  |  |  |
| 6   | Payment for expert testimony  | None |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| 7   | Support for attending   | None |  |  |  |
|     | meetings and/or travel  |      |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| 8   | Patents planned, issued or  | None |  |  |  |
|     | pending   |      |  |  |  |
|     |   |      |  |  |  |
| 9   | Participation on a Data   | None |  |  |  |
|     | Safety Monitoring Board or  |      |  |  |  |
|     | Advisory Board  |      |  |  |  |
| 10  | Leadership or fiduciary role  | None |  |  |  |
|     | in other board, society,  |      |  |  |  |
|     | committee or advocacy   |      |  |  |  |
|     | group, paid or unpaid   |      |  |  |  |
| 11  | Stock or stock options  | None |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| 12  | Receipt of equipment,<br>materials, drugs, medical                    | None |  |  |  |
|     |   |      |  |  |  |
|     | writing, gifts or other   |      |  |  |  |
| 13  | services  Other financial or non-                                     | None |  |  |  |
| 13  | financial interests   | None |  |  |  |
|     | illialiciai illielesis  |      |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| PΙΔ | Please summarize the above conflict of interest in the following box: |      |  |  |  |
|     |   |      |  |  |  |
|     | The author has no conflicts of interest to declare.                   |      |  |  |  |

| R |
|---|
|   |
|   |
| } |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None  |   |
|   |   | Time frame: past  | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | None  |   |
| 3 | Royalties or licenses   | None  |   |
| 4 | Consulting fees   | None  |   |

| 5   | Payment or honoraria for  | None |  |  |  |
|-----|---|------|--|--|--|
|     | lectures, presentations,  |      |  |  |  |
|     | speakers bureaus,   |      |  |  |  |
|     | manuscript writing or   |      |  |  |  |
|     | educational events  |      |  |  |  |
| 6   | Payment for expert testimony  | None |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| 7   | Support for attending   | None |  |  |  |
|     | meetings and/or travel  |      |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| 8   | Patents planned, issued or  | None |  |  |  |
|     | pending   |      |  |  |  |
|     |   |      |  |  |  |
| 9   | Participation on a Data   | None |  |  |  |
|     | Safety Monitoring Board or  |      |  |  |  |
|     | Advisory Board  |      |  |  |  |
| 10  | Leadership or fiduciary role  | None |  |  |  |
|     | in other board, society,  |      |  |  |  |
|     | committee or advocacy   |      |  |  |  |
|     | group, paid or unpaid   |      |  |  |  |
| 11  | Stock or stock options  | None |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| 12  | Receipt of equipment,<br>materials, drugs, medical                    | None |  |  |  |
|     |   |      |  |  |  |
|     | writing, gifts or other   |      |  |  |  |
| 13  | services  Other financial or non-                                     | None |  |  |  |
| 13  | financial interests   | None |  |  |  |
|     | illialiciai illielesis  |      |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| PΙΔ | Please summarize the above conflict of interest in the following box: |      |  |  |  |
|     |   |      |  |  |  |
|     | The author has no conflicts of interest to declare.                   |      |  |  |  |

| Date: _2022-3-28   |
|--|
| Your Name:_Qinfu Ran   |
| Manuscript Title:_Effects of 2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione on autophagy and the PI3K/AKT/mTOF |
| signaling pathway in human cholangiocarcinoma QBC939 cells   |
| Manuscript number (if known):  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None   |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | None   |   |
| 3 | Royalties or licenses   | None   |   |
| 4 | Consulting fees   | None   |   |

| 5   | Payment or honoraria for  | None |  |  |  |
|-----|---|------|--|--|--|
|     | lectures, presentations,  |      |  |  |  |
|     | speakers bureaus,   |      |  |  |  |
|     | manuscript writing or   |      |  |  |  |
|     | educational events  |      |  |  |  |
| 6   | Payment for expert testimony  | None |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| 7   | Support for attending   | None |  |  |  |
|     | meetings and/or travel  |      |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| 8   | Patents planned, issued or  | None |  |  |  |
|     | pending   |      |  |  |  |
|     |   |      |  |  |  |
| 9   | Participation on a Data   | None |  |  |  |
|     | Safety Monitoring Board or  |      |  |  |  |
|     | Advisory Board  |      |  |  |  |
| 10  | Leadership or fiduciary role  | None |  |  |  |
|     | in other board, society,  |      |  |  |  |
|     | committee or advocacy   |      |  |  |  |
|     | group, paid or unpaid   |      |  |  |  |
| 11  | Stock or stock options  | None |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| 12  | Receipt of equipment,<br>materials, drugs, medical                    | None |  |  |  |
|     |   |      |  |  |  |
|     | writing, gifts or other   |      |  |  |  |
| 13  | services  Other financial or non-                                     | None |  |  |  |
| 13  | financial interests   | None |  |  |  |
|     | illialiciai illielesis  |      |  |  |  |
|     |   |      |  |  |  |
|     |   |      |  |  |  |
| PΙΔ | Please summarize the above conflict of interest in the following box: |      |  |  |  |
|     |   |      |  |  |  |
|     | The author has no conflicts of interest to declare.                   |      |  |  |  |

| Date:_2022-3-28  |
|--|
| Your Name:_Chuangye Han  |
| Manuscript Title:_Effects of 2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione on autophagy and the PI3K/AKT/mTOF |
| signaling pathway in human cholangiocarcinoma QBC939 cells   |
| Manuscript number (if known):  |
|  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work |
|---|---|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None  |   |
|   |   | Time frame: past  | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | None  |   |
| 3 | Royalties or licenses   | None  |   |
| 4 | Consulting fees   | None  |   |

| 5   | Payment or honoraria for lectures, presentations,                     | None |  |  |
|-----|---|------|--|--|
|     |   |      |  |  |
|     | speakers bureaus,   |      |  |  |
|     | manuscript writing or   |      |  |  |
|     | educational events  |      |  |  |
| 6   | Payment for expert  | None |  |  |
|     | testimony   |      |  |  |
|     |   |      |  |  |
| 7   | Support for attending   | None |  |  |
|     | meetings and/or travel  |      |  |  |
|     |   |      |  |  |
|     |   |      |  |  |
|     |   |      |  |  |
| 8   | Patents planned, issued or  | None |  |  |
|     | pending   |      |  |  |
|     |   |      |  |  |
| 9   | Participation on a Data   | None |  |  |
|     | Safety Monitoring Board or  |      |  |  |
|     | Advisory Board  |      |  |  |
| 10  | Leadership or fiduciary role  | None |  |  |
|     | in other board, society,  |      |  |  |
|     | committee or advocacy   |      |  |  |
|     | group, paid or unpaid   |      |  |  |
| 11  | Stock or stock options  | None |  |  |
|     |   |      |  |  |
|     |   |      |  |  |
| 12  | Receipt of equipment, materials, drugs, medical                       | None |  |  |
|     |   |      |  |  |
|     | writing, gifts or other   |      |  |  |
|     | services  |      |  |  |
| 13  | Other financial or non-   | None |  |  |
|     | financial interests   |      |  |  |
|     |   |      |  |  |
|     |   |      |  |  |
|     |   |      |  |  |
| Ple | Please summarize the above conflict of interest in the following box: |      |  |  |
| Г   |   |      |  |  |
|     | The author has no conflicts of interest to declare.                   |      |  |  |

| OR |
|----|
|    |
|    |
|    |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |  |  |
|---|---|--|---|--|--|
|   | Time frame: Since the initial planning of the work      |  |   |  |  |
| 1 | All support for the present                             | None   |   |  |  |
|   | manuscript (e.g., funding,                              |  |   |  |  |
|   | provision of study materials,                           |  |   |  |  |
|   | medical writing, article                                |  |   |  |  |
|   | processing charges, etc.)  No time limit for this item. |  |   |  |  |
|   | No time limit for this item.                            |  |   |  |  |
|   |   |  |   |  |  |
|   |   |  |   |  |  |
|   |   | Time frame: past   | 36 months   |  |  |
| 2 | Grants or contracts from                                | None   |   |  |  |
|   | any entity (if not indicated                            |  |   |  |  |
|   | in item #1 above).                                      |  |   |  |  |
| 3 | Royalties or licenses                                   | None   |   |  |  |
|   |   |  |   |  |  |
|   |   |  |   |  |  |
| 4 | Consulting fees   | None   |   |  |  |
|   |   |  |   |  |  |

| 5  | Payment or honoraria for   | None |  |  |
|----|--|------|--|--|
|    | lectures, presentations,   |      |  |  |
|    | speakers bureaus,  |      |  |  |
|    | manuscript writing or  |      |  |  |
|    | educational events   |      |  |  |
| 6  | Payment for expert   | None |  |  |
|    | testimony  |      |  |  |
|    |  |      |  |  |
| 7  | Support for attending  | None |  |  |
|    | meetings and/or travel   |      |  |  |
|    |  |      |  |  |
|    |  |      |  |  |
|    |  |      |  |  |
|    | 5  | N.   |  |  |
| 8  | Patents planned, issued or   | None |  |  |
|    | pending  |      |  |  |
|    |  |      |  |  |
| 9  | Participation on a Data  | None |  |  |
|    | Safety Monitoring Board or   |      |  |  |
|    | Advisory Board   |      |  |  |
| 10 | Leadership or fiduciary role   | None |  |  |
|    | in other board, society,   |      |  |  |
|    | committee or advocacy  |      |  |  |
|    | group, paid or unpaid  |      |  |  |
| 11 | Stock or stock options   | None |  |  |
|    |  |      |  |  |
|    |  |      |  |  |
| 12 | Receipt of equipment,  | None |  |  |
|    | materials, drugs, medical  |      |  |  |
|    | writing, gifts or other  |      |  |  |
|    | services   |      |  |  |
| 13 | Other financial or non-  | None |  |  |
|    | financial interests  |      |  |  |
|    | This is a second of the second |      |  |  |
|    |  |      |  |  |
|    |  |      |  |  |
| וח | Disease summersing the phase conflict of interest in the fall-suring have  |      |  |  |
| PI | Please summarize the above conflict of interest in the following box:  |      |  |  |
| Г  |  |      |  |  |
|    | The author has no conflicts of interest to declare.  |      |  |  |